TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983